MELATONIN SPREČAVA OŠTEĆENJE BUBREGA IZAZVANO LIPOPOLISAHARIDOM KOD PACOVA
Sažetak
Lipopolisaharid (LPS) je sastavni deo ćelijskih zidova gram-negativnih bakterija, tako da je LPS injekcija široko primenjena kao model eksperimentalne akutne bubrežne insuficijencije povezane sa sepsom. Sepsa indukovana LPS-om uzrokovana je prekomernim lučenjem proinflamatornih medijatora i reaktivnih vrsta kiseonika (ROS). Neurohormon melatonin, koji uglavnom luči epifiza, reguliše cirkadijalni ritam, ima antiinflamatornu i imunoregulatornu ulogu. Pokazalo se da melatonin i njegovi metaboliti uklanjaju različite slobodne radikale i intermedijere reaktivnog kiseonika. Cilj ovog istraživanja bio je da se proceni efekat melatonina u prevenciji endoksemije izazvane oštećenjem bubrega izazvanog LPS-om, analizom nivoa uree i kreatinina u krvnom serumu pacova. Dvadeset osam Wistar albino pacova nasumično je podeljeno u četiri grupe (n = 7 po grupi) na sledeći način: 1) Kontrolna grupa, 2) MLT grupa (50 mg/kg, oralno), 3) LPS grupa (10 mg/kg, i.p.) i 4) LPS + MLT grupa (10 mg/kg + 50 mg/kg). Nivoi kreatinina i uree u serumu (p < 0,05) bili su značajno viši kod životinja tretiranih LPS-om u poređenju životinjama iz kontrolne grupe. Zajednički tretman životinja sa sepsom indukovanom LPS-om i MLT značajno je smanjio visok nivo serumskog kreatinina i uree (p < 0,05). Može se zaključiti da oralna primena melatonina značajno ublažava akutnu nefrotoksičnost izazvanu LPS-om kod pacova. Verovatno je da su korisni efekti melatonina povezani sa njegovim poznatim antioksidativnim efektima na bubrežno tkivo, a potencijalno i sa nekim drugim manje poznatim mehanizmima dejstva.
Reference
800x600
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
DefSemiHidden="false" DefQFormat="false" DefPriority="99"
LatentStyleCount="371">
UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
Name="index 1"/>
Name="index 2"/>
Name="index 3"/>
Name="index 4"/>
Name="index 5"/>
Name="index 6"/>
Name="index 7"/>
Name="index 8"/>
Name="index 9"/>
UnhideWhenUsed="true" Name="toc 1"/>
UnhideWhenUsed="true" Name="toc 2"/>
UnhideWhenUsed="true" Name="toc 3"/>
UnhideWhenUsed="true" Name="toc 4"/>
UnhideWhenUsed="true" Name="toc 5"/>
UnhideWhenUsed="true" Name="toc 6"/>
UnhideWhenUsed="true" Name="toc 7"/>
UnhideWhenUsed="true" Name="toc 8"/>
UnhideWhenUsed="true" Name="toc 9"/>
Name="Normal Indent"/>
Name="footnote text"/>
Name="annotation text"/>
Name="header"/>
Name="footer"/>
Name="index heading"/>
UnhideWhenUsed="true" QFormat="true" Name="caption"/>
Name="table of figures"/>
Name="envelope address"/>
Name="envelope return"/>
Name="footnote reference"/>
Name="annotation reference"/>
Name="line number"/>
Name="page number"/>
Name="endnote reference"/>
Name="endnote text"/>
Name="table of authorities"/>
Name="macro"/>
Name="toa heading"/>
Name="List"/>
Name="List Bullet"/>
Name="List Number"/>
Name="List 2"/>
Name="List 3"/>
Name="List 4"/>
Name="List 5"/>
Name="List Bullet 2"/>
Name="List Bullet 3"/>
Name="List Bullet 4"/>
Name="List Bullet 5"/>
Name="List Number 2"/>
Name="List Number 3"/>
Name="List Number 4"/>
Name="List Number 5"/>
Name="Closing"/>
Name="Signature"/>
UnhideWhenUsed="true" Name="Default Paragraph Font"/>
UnhideWhenUsed="true" Name="Body Text"/>
Name="Body Text Indent"/>
Name="List Continue"/>
Name="List Continue 2"/>
Name="List Continue 3"/>
Name="List Continue 4"/>
Name="List Continue 5"/>
Name="Message Header"/>
Name="Salutation"/>
Name="Date"/>
Name="Body Text First Indent"/>
Name="Body Text First Indent 2"/>
Name="Note Heading"/>
Name="Body Text 2"/>
Name="Body Text 3"/>
Name="Body Text Indent 2"/>
Name="Body Text Indent 3"/>
Name="Block Text"/>
Name="Hyperlink"/>
Name="FollowedHyperlink"/>
Name="Document Map"/>
Name="Plain Text"/>
Name="E-mail Signature"/>
Name="HTML Top of Form"/>
Name="HTML Bottom of Form"/>
Name="Normal (Web)"/>
Name="HTML Acronym"/>
Name="HTML Address"/>
Name="HTML Cite"/>
Name="HTML Code"/>
Name="HTML Definition"/>
Name="HTML Keyboard"/>
Name="HTML Preformatted"/>
Name="HTML Sample"/>
Name="HTML Typewriter"/>
Name="HTML Variable"/>
Name="Normal Table"/>
Name="annotation subject"/>
Name="No List"/>
Name="Outline List 1"/>
Name="Outline List 2"/>
Name="Outline List 3"/>
Name="Table Simple 1"/>
Name="Table Simple 2"/>
Name="Table Simple 3"/>
Name="Table Classic 1"/>
Name="Table Classic 2"/>
Name="Table Classic 3"/>
Name="Table Classic 4"/>
Name="Table Colorful 1"/>
Name="Table Colorful 2"/>
Name="Table Colorful 3"/>
Name="Table Columns 1"/>
Name="Table Columns 2"/>
Name="Table Columns 3"/>
Name="Table Columns 4"/>
Name="Table Columns 5"/>
Name="Table Grid 1"/>
Name="Table Grid 2"/>
Name="Table Grid 3"/>
Name="Table Grid 4"/>
Name="Table Grid 5"/>
Name="Table Grid 6"/>
Name="Table Grid 7"/>
Name="Table Grid 8"/>
Name="Table List 1"/>
Name="Table List 2"/>
Name="Table List 3"/>
Name="Table List 4"/>
Name="Table List 5"/>
Name="Table List 6"/>
Name="Table List 7"/>
Name="Table List 8"/>
Name="Table 3D effects 1"/>
Name="Table 3D effects 2"/>
Name="Table 3D effects 3"/>
Name="Table Contemporary"/>
Name="Table Elegant"/>
Name="Table Professional"/>
Name="Table Subtle 1"/>
Name="Table Subtle 2"/>
Name="Table Web 1"/>
Name="Table Web 2"/>
Name="Table Web 3"/>
Name="Balloon Text"/>
Name="Table Theme"/>
Name="List Paragraph"/>
Name="Intense Quote"/>
Name="Subtle Emphasis"/>
Name="Intense Emphasis"/>
Name="Subtle Reference"/>
Name="Intense Reference"/>
UnhideWhenUsed="true" Name="Bibliography"/>
UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
Name="Grid Table 1 Light Accent 1"/>
Name="Grid Table 6 Colorful Accent 1"/>
Name="Grid Table 7 Colorful Accent 1"/>
Name="Grid Table 1 Light Accent 2"/>
Name="Grid Table 6 Colorful Accent 2"/>
Name="Grid Table 7 Colorful Accent 2"/>
Name="Grid Table 1 Light Accent 3"/>
Name="Grid Table 6 Colorful Accent 3"/>
Name="Grid Table 7 Colorful Accent 3"/>
Name="Grid Table 1 Light Accent 4"/>
Name="Grid Table 6 Colorful Accent 4"/>
Name="Grid Table 7 Colorful Accent 4"/>
Name="Grid Table 1 Light Accent 5"/>
Name="Grid Table 6 Colorful Accent 5"/>
Name="Grid Table 7 Colorful Accent 5"/>
Name="Grid Table 1 Light Accent 6"/>
Name="Grid Table 6 Colorful Accent 6"/>
Name="Grid Table 7 Colorful Accent 6"/>
Name="List Table 1 Light Accent 1"/>
Name="List Table 6 Colorful Accent 1"/>
Name="List Table 7 Colorful Accent 1"/>
Name="List Table 1 Light Accent 2"/>
Name="List Table 6 Colorful Accent 2"/>
Name="List Table 7 Colorful Accent 2"/>
Name="List Table 1 Light Accent 3"/>
Name="List Table 6 Colorful Accent 3"/>
Name="List Table 7 Colorful Accent 3"/>
Name="List Table 1 Light Accent 4"/>
Name="List Table 6 Colorful Accent 4"/>
Name="List Table 7 Colorful Accent 4"/>
Name="List Table 1 Light Accent 5"/>
Name="List Table 6 Colorful Accent 5"/>
Name="List Table 7 Colorful Accent 5"/>
Name="List Table 1 Light Accent 6"/>
Name="List Table 6 Colorful Accent 6"/>
Name="List Table 7 Colorful Accent 6"/>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman","serif";}
1. Jiang W Xu J, Shen B, Wang Y, Teng J, Ding X. Acute kidney injury risk assessment. Contrib Nephrol 2018; 193: 13–20. [CrossRef] [PubMed]
2. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159–69. [CrossRef] [PubMed]
3. Millar CGM, Theimermann C. Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. Br J Pharmacol 1997; 121: 1824–30. [CrossRef] [PubMed]
4. Shi Y, Hua Q, Li N, Zhao M, Cui Y. Protective effects of evodiamine against LPS-induced acute kidney injury through regulation of ROS-NF-kB-mediated inflammation. Evid Based Complement Alternat Med. 2019 Mar 3; 2019: 2190847. [CrossRef] [PubMed]
5. Chung-Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55. [CrossRef] [PubMed]
6. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351: 1501-5. [CrossRef] [PubMed]
7. Alobaidi R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-Associated Acute Kidney Injury. Semin Nephrol 2015; 35: 2–11. [CrossRef] [PubMed]
8. Kumar S, Tripathy S, Jyoti A, Singh SG. Recent advances in biosensors for diagnosis and detection of sepsis: A comprehensive review. Biosens Bioelectron 2019; 124-125: 205-15. [CrossRef] [PubMed]
9. Chen Y, Luan L, Wang C, Song M, Zhao Y, Yao Y, Yang H, Ma B, Fan H. Dexmedetomidine protects against lipopolysaccharide-induced early acute kidney injury by inhibiting the iNOS/NO signaling pathway in rats. Nitric Oxide 2019; 85: 1–9. [CrossRef] [PubMed]
10. Chen Y, Jin S, Teng X, Hu Z, Zhang Z, Qiu X, Tian D, Wu Y. Hydrogen sulfide attenuates LPS-induced acute kidney injury by inhibiting inflammation and oxidative stress. Oxid Med Cell Longev. 2018; 2018:6717212. [CrossRef] [PubMed]
11. Khajevand-Khazaei MR, Azimi S, Sedighnejad L, Salari S, Ghorbanpour A, Baluchnejadmojarad T, et al. S-allyl cysteine protects against lipopolysaccharide induced acute kidney injury in the C57BL/6 mouse strain: Involvement of oxidative stress and inflammation. Int Immunopharmacol 2019; 69: 19–26. [CrossRef] [PubMed]
12. Ahmadiasl N, Banaei S, Alihemmati A. Combination antioxidant effect of erythropoietin and melatonin on renal ischemiareperfusion injury in rats. Iran J Basic Med Sci 2013; 16: 1209-16. [PubMed]
13. Reiter RJ, Tan DX, Kim SJ, Cruz MH. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 2014; 219:1873–87. [CrossRef] [PubMed]
14. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res 2015; 59: 403–9. [CrossRef] [PubMed]
15. Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J Pineal Res 2014; 58: 107–16. [CrossRef] [PubMed]
16. Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Ageing Dev 2002; 123: 1007–19. [CrossRef] [PubMed]
17. Gholamnezhad Z, Fatehi Hassanabad Z. Effects of lipopolysaccharide induced septic shock on rat isolated kidney, possible role of nitric oxide and protein kinase C pathways. Iran J Basic Med Sci 2018;21(10):1073–8. [CrossRef] [PubMed]
18. Potic, M, Ignjatovic, I, Nickovic, VP, Zivkovic JB, Krdzic JD, Mitic JS, et al. Two different melatonin treatment regimens prevent an increase in kidney injury marker-1 induced by carbon tetrachloride in rat kidneys. Can J Physiol Pharm 2019; 97: 422–8. [CrossRef] [PubMed]
19. Kamal F, Snook L, Saikumar JH. Rhabdomyolysis-Associated Acute Kidney Injury With Normal Creatine Phosphokinase. Am J Med Sci 2018; 355(1): 84-7. [CrossRef] [PubMed]
20. Lee S, Kim S, Kang KP, Moon SO, Sung MJ, Kim DH, et al. Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057-65. [CrossRef] [PubMed]
21. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol 1998; 275: H416–H421. [CrossRef] [PubMed]
22. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168: 5817–23. [CrossRef] [PubMed]
23. Schrier RW and Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159–69. [CrossRef] [PubMed]
24. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Investig 2009; 119: 2868–78. [CrossRef] [PubMed]
25. Coulombe JJ, Favreau L. A new simple semimicro method for colorimetric determination of urea. Clin Chem 1963; 9: 102–8. [CrossRef] [PubMed]
26. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006; 38: 623–27. [CrossRef] [PubMed]
27. Tan D, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34: 75–8. [CrossRef] [PubMed]
28. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of Melatonin in the Reduction of Oxidative Stress. J Biomed Sci 2000; 7: 444–58. [CrossRef] [PubMed]
29. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336: 1186-95. [CrossRef] [PubMed]
30. Nava M, Romero F, Quiroz Y, Parra G, Bonet L, Rodriguez-Iturbe B. Melatonin Attenuates Acute Renal Failure and Oxidative Stress Induced by Mercuric Chloride in Rats. Am J Physiol 2000; 279: F910–F918. [CrossRef] [PubMed]
31. Montilla P, Tunez I, Munoz MC, Lopez A, Soria JV. Hyperlipidemic Nephropathy Induced by Adriamycin: Effect of Melatonin Administration. Nephron 1997; 76: 345–50. [CrossRef] [PubMed]
32. Ferraz FF, Kos AG, Janino P, Homsi E. Effects of melatonin administration to rats with glycerol-induced acute renal failure. Ren 2002; 24(6): 735-46. [CrossRef] [PubMed]
33. Escames G, León J, Macías M, Khaldy H, Acuña-Castroviejo D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003; 17(8): 932-4. [CrossRef] [PubMed]